FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295067230> ?p ?o ?g. }

• W4295067230 endingPage "524" @default.
• W4295067230 startingPage "517" @default.
• W4295067230 abstract "OBJECTIVE In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. METHODS The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. RESULTS Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. CONCLUSIONS End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases." @default.
• W4295067230 created "2022-09-10" @default.
• W4295067230 creator A5002292188 @default.
• W4295067230 creator A5014312128 @default.
• W4295067230 creator A5021212114 @default.
• W4295067230 creator A5024065685 @default.
• W4295067230 creator A5033328975 @default.
• W4295067230 creator A5035360381 @default.
• W4295067230 creator A5040079244 @default.
• W4295067230 creator A5046867279 @default.
• W4295067230 creator A5049029124 @default.
• W4295067230 creator A5056820514 @default.
• W4295067230 creator A5059978777 @default.
• W4295067230 creator A5060210676 @default.
• W4295067230 creator A5060929910 @default.
• W4295067230 creator A5076391720 @default.
• W4295067230 creator A5077366696 @default.
• W4295067230 date "2022-11-01" @default.
• W4295067230 modified "2023-10-16" @default.
• W4295067230 title "Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset" @default.
• W4295067230 cites W1518394182 @default.
• W4295067230 cites W1975370377 @default.
• W4295067230 cites W1975572781 @default.
• W4295067230 cites W1988073264 @default.
• W4295067230 cites W2006259198 @default.
• W4295067230 cites W2006855472 @default.
• W4295067230 cites W2038638439 @default.
• W4295067230 cites W2043536578 @default.
• W4295067230 cites W2046461751 @default.
• W4295067230 cites W2076408368 @default.
• W4295067230 cites W2081396783 @default.
• W4295067230 cites W2093990360 @default.
• W4295067230 cites W2101095958 @default.
• W4295067230 cites W2149296823 @default.
• W4295067230 cites W2224583964 @default.
• W4295067230 cites W2322626420 @default.
• W4295067230 cites W2613509884 @default.
• W4295067230 cites W2727345885 @default.
• W4295067230 cites W2791156200 @default.
• W4295067230 cites W2894276525 @default.
• W4295067230 cites W2968758063 @default.
• W4295067230 cites W2990263159 @default.
• W4295067230 cites W3018314405 @default.
• W4295067230 cites W3046340124 @default.
• W4295067230 cites W3084129397 @default.
• W4295067230 cites W3211085456 @default.
• W4295067230 doi "https://doi.org/10.3171/2022.8.peds22301" @default.
• W4295067230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36087334" @default.
• W4295067230 hasPublicationYear "2022" @default.
• W4295067230 type Work @default.
• W4295067230 citedByCount "0" @default.
• W4295067230 crossrefType "journal-article" @default.
• W4295067230 hasAuthorship W4295067230A5002292188 @default.
• W4295067230 hasAuthorship W4295067230A5014312128 @default.
• W4295067230 hasAuthorship W4295067230A5021212114 @default.
• W4295067230 hasAuthorship W4295067230A5024065685 @default.
• W4295067230 hasAuthorship W4295067230A5033328975 @default.
• W4295067230 hasAuthorship W4295067230A5035360381 @default.
• W4295067230 hasAuthorship W4295067230A5040079244 @default.
• W4295067230 hasAuthorship W4295067230A5046867279 @default.
• W4295067230 hasAuthorship W4295067230A5049029124 @default.
• W4295067230 hasAuthorship W4295067230A5056820514 @default.
• W4295067230 hasAuthorship W4295067230A5059978777 @default.
• W4295067230 hasAuthorship W4295067230A5060210676 @default.
• W4295067230 hasAuthorship W4295067230A5060929910 @default.
• W4295067230 hasAuthorship W4295067230A5076391720 @default.
• W4295067230 hasAuthorship W4295067230A5077366696 @default.
• W4295067230 hasConcept C121608353 @default.
• W4295067230 hasConcept C126322002 @default.
• W4295067230 hasConcept C126838900 @default.
• W4295067230 hasConcept C141071460 @default.
• W4295067230 hasConcept C142724271 @default.
• W4295067230 hasConcept C207886595 @default.
• W4295067230 hasConcept C2776141087 @default.
• W4295067230 hasConcept C2776694085 @default.
• W4295067230 hasConcept C2776938808 @default.
• W4295067230 hasConcept C2778424827 @default.
• W4295067230 hasConcept C2778895204 @default.
• W4295067230 hasConcept C2780192828 @default.
• W4295067230 hasConcept C2780775027 @default.
• W4295067230 hasConcept C2781156865 @default.
• W4295067230 hasConcept C509974204 @default.
• W4295067230 hasConcept C71924100 @default.
• W4295067230 hasConceptScore W4295067230C121608353 @default.
• W4295067230 hasConceptScore W4295067230C126322002 @default.
• W4295067230 hasConceptScore W4295067230C126838900 @default.
• W4295067230 hasConceptScore W4295067230C141071460 @default.
• W4295067230 hasConceptScore W4295067230C142724271 @default.
• W4295067230 hasConceptScore W4295067230C207886595 @default.
• W4295067230 hasConceptScore W4295067230C2776141087 @default.
• W4295067230 hasConceptScore W4295067230C2776694085 @default.
• W4295067230 hasConceptScore W4295067230C2776938808 @default.
• W4295067230 hasConceptScore W4295067230C2778424827 @default.
• W4295067230 hasConceptScore W4295067230C2778895204 @default.
• W4295067230 hasConceptScore W4295067230C2780192828 @default.
• W4295067230 hasConceptScore W4295067230C2780775027 @default.
• W4295067230 hasConceptScore W4295067230C2781156865 @default.
• W4295067230 hasConceptScore W4295067230C509974204 @default.

• next